Globeimmune, Inc.
18 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
6
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 30, 2026The maintenance fee for Yeast-based vaccines (US 9,066,893) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
- 1 fee due Apr 15, 2027The maintenance fee for Compositions and methods for the treatment or prevention of hepatitis B virus infection (US 10,441,650) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due Jun 1, 2027The maintenance fee for Yeast-Brachyury Immunotherapeutic Compositions (US 9,198,941) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
- 1 fee due Aug 9, 2027The maintenance fee for Compositions and methods for the treatment or prevention of human adenovirus-36 infection (US 9,254,320) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.
- 2 fees due Sep 17 to 22, 2027 · next Sep 17
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,745,128 | Ras mutation and compositions and methods related thereto In force · From the USPTO record | In force | From the USPTO record | |
| US 9,333,246 | Compositions and methods to elicit immune responses against pathogenic organisms using yeast-based vaccines In force · From the USPTO record | In force | From the USPTO record | |
| US 8,470,313 | Ras mutation and compositions and methods related thereto In force · From the USPTO record | In force | From the USPTO record | |
| US 8,460,919 | Compositions and methods to elicit immune responses against pathogenic organisms using yeast based vaccines In force · From the USPTO record | In force | From the USPTO record | |
| US 9,549,970 | Methods for producing yeast-based vaccines In force · From the USPTO record | In force | From the USPTO record | |
| US 9,066,893 | Yeast-based vaccines In force · From the USPTO record | In force | From the USPTO record | |
| US 9,254,320 | Compositions and methods for the treatment or prevention of human adenovirus-36 infection In force · From the USPTO record | In force | From the USPTO record | |
| US 8,722,054 | Compositions and methods for the treatment or prevention of hepatitis B virus infection In force · From the USPTO record | In force | From the USPTO record | |
| US 8,877,205 | Yeast-based therapeutic for chronic hepatitis B infection In force · From the USPTO record | In force | From the USPTO record | |
| US 8,961,988 | Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 24: 18 patents in force now held by others · 8 lapsed for an unpaid fee · 11 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned · 10 no status recorded